Cost-effectiveness Analysis Of Medication In Acute Cerebral Infarction

Cerebral infarction(CI) is a common disease that it's incidence rate, Mutilation rate and case-fatality rate are high. Influential factors of CI are more, their interactions makes prevention and cure difficulty. All the time, people didn't find a therapeutic regimen which is sure, available. New drugs manufacture and apply unceasingly, therapeutic effect of acute CI are elevating quickly.Besides therapeutic effects, new drugs are bringing cost-increasing. The article plan to evaluate four therapeutic regimens with CEA, and find the best one which is available ,safe and economic. Method: 389 cases of cerebral infarction, admitted from march to July 2003,were collected and divided into four groups: I traditional Chinese drug group, II western medicine groupIIItraditional Chinese drug +brain protectant group, IVwestern medicine +brain protectant group. Cost was calculated by the drug prices and real medication at that time. Data was evaluated using pharmacoeconomic cost-effectiveness analysis. Results: The average age 64.4 ?11.9, and 86.0% of them are above60 years old. The constituent ratio is increasing by age. Past history diseases are hypertension, heart disease history, diabetes, hyperlipemia, smoking and drinking by turns. The average visit time is 159.0 + 512.2 hour, and 33.7% patients visit time larger than 72 hours. The cost of four groups were 1246.7yuan, 3130.0yuan, 2712.1yuan and 3657.7yuan respectively. The effective rates of four groups were 71.4%, 70.0%, 69.2% and 72.6%. The CER of four groups are 17.5, 44.7, 39.2 and 50.4. The ICER are 523.6 and 278.2yuan. Conclusion: We conclusion that cerebrovascular disease propaganda should be given to the population over 60 years old. So that they could recognize this disease, shorten the visit time and improve the prognosis. Among the four schemes, scheme I had the lowest CER, and had the high effective rate, we can think the scheme I is the ideal one, but we should improve it because of it's few cases. At the end the ideal therapeutic regimen is scheme IV.